DAXOR CORP Stock Price, News & Analysis

Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has scheduled an investor conference call for Thursday, March 6, 2025, at 4:30 p.m. ET. During the call, President and CEO Michael Feldschuh and CFO Robert Michel will present the company's fiscal year 2024 financial results and provide updates on corporate developments. The event will include a Q&A session, with investors having the option to submit questions in advance via email. A webcast replay will be available on Daxor.com following the call.

Daxor (DXR) reported significant progress in 2024 and early 2025, with notable financial and operational achievements. The company's net assets reached $36,789,893 ($7.25 per share) as of December 31, 2024, up from $34,010,384 ($7.08 per share) in 2023.

Key financial highlights include:

• Revenue growth of 116.5% year-over-year in 2024
• 60.1% increase in diagnostic system kit sales
• 12 new accounts in 2024 and 3 in early 2025
• Operating division achieved cash-flow break-even in Q1 2025
• Secured $2.5M DoD contract and $350K in additional funding

The company entered an agreement to acquire IP from its supplier for in-house manufacturing of Volumex and Glofil products. Daxor is preparing to resubmit FDA 510(k) application for its next-generation blood volume analyzer, which promises faster results and improved functionality. The company aims to transition from an investment company to an operating company designation by the end of 2025.

Daxor (DXR) reported significant progress in 2024 and early 2025, establishing itself as the global leader in blood volume measurement technology. The company achieved notable financial milestones, with net assets reaching $36,789,893 ($7.25 per share) as of December 31, 2024, up from $34,010,384 ($7.08 per share) in 2023.

Key achievements include:

• Revenue growth of 116.5% year-over-year in 2024
• 60.1% increase in diagnostic system kit sales
• 12 new accounts in 2024 and 3 in early 2025
• $2.5M DoD contract and $350K in grants from Launch Tennessee and NIH
• Operating division reached cash-flow break-even in Q1 2025

The company is preparing to launch its next-generation blood volume analyzer, which promises to be three times faster and simpler than current systems. Daxor also entered an agreement to acquire IP from its supplier to bring manufacturing in-house for Volumex and add Glo-fil to its product offerings.

Daxor (DXR) reported significant growth in its fiscal year 2024, with its NAV increasing to $7.25 per share from $7.08 in 2023. The company's operating division achieved remarkable results, including a 116.5% revenue increase year-over-year.

Key highlights include:

• 60.1% growth in diagnostic kit sales
• 12 new customer accounts in 2024
• Achievement of cash-flow break-even in Q1 2025 (excluding non-cash expenses)
• Secured $2.5M DoD contract
• Received over $350K in NIH and Launch Tennessee grants

The company is preparing to file for FDA approval of its next-generation blood volume analyzer through the 510(k) pathway. This point-of-care system aims to enhance clinical workflows in critical care settings and expand market opportunities in both hospital and outpatient environments.

Daxor (DXR) has expanded its blood volume analysis (BVA) services to a major 735-bed Midwest healthcare facility. The healthcare center will implement Daxor's ezBVA Lab service for outpatient cardiovascular care, focusing on patients with heart failure and hypertension.

Blood samples will be processed at Daxor's CLIA-certified Tennessee facility, providing comprehensive BVA results within 24 hours. The BVA diagnostic offers 98% accuracy in fluid management data, helping clinicians optimize patient care. The service is fully reimbursable through CPT codes for both inpatient and outpatient settings under public and private insurance plans.

Daxor (Nasdaq: DXR) has expanded its blood volume analysis (BVA) technology to two major hospitals within New Jersey's largest academic health care system. The hospitals are implementing on-site BVA analyzers to enable immediate access to precise blood volume measurements for critical care decisions.

The implementation aims to optimize fluid management, reduce hospital stays, and improve outcomes for heart failure and critical care patients. According to CEO Michael Feldschuh, the expansion demonstrates the effectiveness of their growth strategy, with dedicated resources in sales and marketing delivering meaningful results. The company expects to maintain this accelerated sales trajectory throughout 2025.

Daxor (DXR) announced new research findings from Duke University Medical Center and Yale School of Medicine presented at the Technology and Heart Failure Therapeutics Conference (THT) in February 2025. The studies focus on the company's Blood Volume Analysis (BVA) technology.

The Duke study revealed no correlation between pulmonary artery pressure readings and actual blood volume measured by BVA, challenging industry assumptions about pressure monitoring as a proxy for volume measurement in heart failure care.

The Yale study, conducted over 5 years, examined diuretic mechanism of action using BVA, demonstrating the technology's accuracy in detecting volume shifts. The research provided new insights into the fluid removal process and highlighted BVA's potential to improve treatment for millions of patients on diuretic therapy.

TruLite Health, developer of health equity solutions, has expanded its leadership team with key appointments. Walter D. Conwell, MD, MBA, former chief diversity officer at Morehouse School of Medicine, has been appointed as president. The company also added two board members: Edmondo Robinson, MD, MBA, a digital health leader and Ardent Health Services board member, and Caleb DesRosiers, JD, MPA, a pharmaceutical executive.

TruLite's main product, Truity™, is software that integrates with electronic health records to address clinical bias at the point of care. The solution uses explainable AI and machine learning to drive patient-specific clinical, social, and behavioral interventions, aiming to improve healthcare outcomes and costs. The software aligns with regulatory requirements from the Joint Commission, CMS, and FDA.

Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, will exhibit at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress in Orlando, FL from February 23-25, 2025, at Booth #532.

The company's Blood Volume Analysis (BVA) technology has demonstrated significant impact in ICU settings, where there are 5.7 million annual admissions costing $108 billion in the United States. Peer-reviewed studies show BVA technology alters fluid and red blood cell interventions in 44% of cases and reduces mortality by 66% in surgical intensive care units, while also decreasing hospital stays and ventilator days.